The Exchange has sought clarification from Sun Pharmaceutical Industries Limited with respect to recent news item captioned Sun Pharma Eyes Stronger US Presence With USD 10 Billion Organon Acquisition. The response from the Company is attached.
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
NSE sought clarification from Sun Pharma on a news report about a potential USD 10 billion acquisition of Organon, which would expand its US generics presence. The company has submitted its response to the exchange, the details of which are attached. Organon is a listed US pharmaceutical company spun off from Merck. A deal of this size would be one of the largest outbound acquisitions by an Indian pharma company. The response is expected to confirm or clarify the company's position on the reported acquisition.
If the USD 10 billion acquisition materializes, it would be transformative for Sun Pharma's US business but could also raise concerns about leverage and integration risk. Shareholders should watch for the actual response text, which will clarify whether the company is formally pursuing the deal or merely evaluating it.